Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

About this update from Prelude Therapeutics Incorporated

[{"type":"text","content":"WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m. ET. A live webcast of the presentation can be accessed by visiting the “Investors” page under the “Events & Presentation” section of the Prelude website, where a replay of the presentation will be available for a limited time. About Prelude Therapeutics Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis. Prelude’s initial clinical candidates, PRT543 and PRT811, are potent, selective, oral PRMT5 inhibitors in Phase 1 development for the treatment of advanced solid tumors, primary and secondary CNS cancers and select myeloid malignancies. PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors. PRT2527, a highly selective CDK9 inhibitor, is anticipated to begin Phase 1 clinical development by year-end as a monotherapy in patients with selected solid tumors. In addition, the Company’s pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs. Investor Contacts:Stacey JurchisonExecutive Director, Corporate [email protected] Melissa ForstArgot [email protected] Media Contact:Paige DonnellyArgot [email protected] \nSource: Prelude Therapeutics, Inc.","length":4015,"tagName":"div"}]

More updates from Prelude Therapeutics Incorporated